PlavinaTMuralidharanKKKuestersG, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology2017; 89(15): 1584–1593.
2.
PortaccioEMoiolaLMartinelliV, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. Neurology2018; 90: e832–e839.
3.
KümpfelTThielSMeinlI, et al. Long-term exposure to natalizumab during pregnancy: A prospective case series from the German multiple sclerosis and pregnancy registry. ECTRIMS Online Libr2017; 52368: 204.
4.
TriplettJDVijayanSRajanayagamS, et al. Pregnancy outcomes amongst multiple sclerosis females with third trimester natalizumab use. Mult Scler Relat Disord2020; 40: 101961.
5.
LandiDPortaccioEBovisF, et al. Continuation of natalizumab versus interruption is associated with lower risk of relapses during pregnancy and postpartum in women with MS. ECTRIMS Online Libr2019; 338: 279583.
6.
DobsonRDassanPRobertsM, et al. UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. Pract Neurol2019; 19(2): 106–114.
7.
MahadevanURobinsonCBernaskoN, et al. Inflammatory bowel disease in pregnancy clinical care pathway: A report from the American gastroenterological association IBD parenthood project working Group. Am J Obstet Gynecol2019; 220: 308–323.
8.
ProschmannUThomasKThielS, et al. Natalizumab during pregnancy and lactation. Mult Scler2018; 24(12): 1627–1634.
9.
HaghikiaALanger-GouldARellensmannG, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol2014; 71: 891–895.
10.
PortaccioEAnnovazziPGhezziA, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology2018; 90: e823–e831.
